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Abstract 
The nickel(II), copper(II) and zinc(II) complexes of the proline-thiosemicarbazone hybrids 3-
methyl-(S)-pyrrolidine-2-carboxylate-2-formylpyridine thiosemicarbazone (L-Pro-FTSC or 
(S)-H2L
1) and 3-methyl-(R)-pyrrolidine-2-carboxylate-2-formylpyridine thiosemicarbazone 
(D-Pro-FTSC or (R)-H2L
1), as well as 3-methyl-(S)-pyrrolidine-2-carboxylate-2-
formylpyridine 4,4-dimethyl-thiosemicarbazone (dm-L-Pro-FTSC or (S)-H2L
2), namely   
[Ni(L-Pro-FTSC2H)]2 (1), [Ni(D-Pro-FTSC2H)]2 (2), [Ni(dm-L-Pro-FTSC2H)]2 (3), 
[Cu(dm-L-Pro-FTSC2H)] (6), [Zn(L-Pro-FTSC2H)] (7) and [Zn(D-Pro-FTSC2H)] (8), in 
addition to two previously reported, [Cu(L-Pro-FTSC2H)] (4), [Cu(D-Pro-FTSC2H)] (5), 
have been synthesized and characterized by elemental analysis, one- and two-dimensional 1H 
and 13C NMR spectroscopy, CD, UV−vis and ESI mass spectrometry. Compounds 13, 6 and 
7 have been also studied by single crystal X-ray diffraction. Magnetic properties and solid 
state high-field EPR spectra of 2 over the range 50420 GHz were investigated. The complex 
formation processes of L-Pro-FTSC with nickel(II) and zinc(II) have been studied in aqueous 
solution due to the excellent water solubility of the complexes via pH-potentiometry, UV−vis 
and 1H NMR spectroscopy. The results of the antiproliferative activity in vitro showed that 
dimethylation improves the cytotoxicity and hR2 RNR inhibition. Therefore introduction of 
more lipophilic groups into thiosemicarbazone-proline backbone becomes an option for the 
synthesis of more efficient cytotoxic agents of this family of compounds.  
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Introduction 
Thiosemicarbazones (TSCs) are known as versatile ligands for various metal ions.1 
Especially their first row transition metal coordination chemistry is well developed.2 Specific 
feature of TSCs and their metal complexes is their broad spectrum of biological properties 
including antiviral, antibacterial, antimalarial, antifungal and anticancer activity.3,4,5,6 α-N-
heterocyclic TSCs (HCTs) are known for their anticancer activity since the 1950s when 2-
formylpyridine thiosemicarbazone was discovered to possess in vivo antileukemic activity in 
a mice model.7 The best studied HCT to date is 3-aminopyridine-2-carboxaldehyde 
thiosemicarbazone (3-AP), also referred to as Triapine, which has already been examined in 
several clinical phase I and II trials.8,9,10 Triapine was found to be safe and effective against 
hematologic malignancies, e.g. leukemia.11,12 A recent clinical phase II study including 37 
patients with aggressive myeloproliferative neoplasms is of particular note since a response 
rate of 49% and complete remission in 24% of all patients has been documented.13 However, 
other clinical phase II studies showed that Triapine is ineffective against a variety of solid 
tumors including pancreatic, adeno-, lung and renal carcinoma.14,15,16,17 In the 1970s it was 
discovered that HCTs are inhibitors of the enzyme ribonucleotide reductase (RNR),18,19 
which catalyzes the rate determining step of DNA synthesis, namely the reduction of 
ribonucleotides to the corresponding 2’-deoxyribonucleotides.20 Several mechanisms of RNR 
inhibition by thiosemicarbazones and especially Triapine have been proposed.18,21 The until 
recently favored mechanistic scheme was that Triapine forms an iron(III) complex within the 
cell, which is reduced to Fe(II)-Triapine by intracellular reductants. Then the iron(II) 
complex reacts with oxygen, which leads to the formation of reactive oxygen species (ROS) 
able to quench the RNR’s tyrosyl radical.22,23,24 However, quite recently it was found that 
quenching of the tyrosyl radical is not oxygen dependent, suggesting that it might be reduced 
directly by the Fe(II)-Triapine complex without involvement of ROS.25  
 
A second known target for HCTs is topoisomerase IIα (Topo IIα) an enzyme which controls 
the DNA topology during cell division by inducing temporary double strand breaks.26,27,28,29 
A series of Topo IIα inhibiting HCTs showed high affinity for the enzymes ATP binding 
pocket, thus acting as catalytic inhibitor of Topo IIα without the generation of DNA double 
strand breaks.30 Although the structureactivity relationships (SARs) for HCTs Topo IIα 
inhibition are far from being completely understood, it was suggested that reaction with 
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copper(II) leading to square-planar complexes enhances the Topo IIα inhibition rate 
significantly.31  
 
Nickel(II)-TSC complexes gained attention in the past few years. The reasons for this are the 
versatile coordination geometry preferences of this metal ion (square-planar, octahedral, 
tetrahedral), the formation of monomeric and dimeric complexes and its ability to mimic to 
some extent platinum(II), which is of great importance in chemotherapy.32,33,34,35,36,37 The 
latter, however, is characterized by quite different ligand exchange rate constants.38 Some 
salicylaldehyde TSC based nickel(II) complexes exhibited higher cytotoxicity than cisplatin 
(cis-diamminedichloridoplatinum(II), CDDP) in human cancer cell lines, while they were 
relatively nontoxic in normal kidney cells, demonstrating the potential of nickel(II)-TSC 
complexes for clinical development.39 Zinc(II) shows low systemic cytotoxicity and forms 
easily TSC complexes. Moreover, the cytotoxicity of the zinc(II) complex is often enhanced 
compared to the free ligand.40,41 A HCT based zinc(II) complex showed comparable 
cytotoxicity to 5-fluorouracil in human  cancer cell lines41 and a polyhydroxybenzaldehyde 
TSC based zinc(II) complex inhibited topoisomerase I.42 
 
One of the great challenges in the design of new TSCs as possible anticancer compounds is to 
find the optimal balance between lipophilicity and water-solubility without losing efficacy. 
Increased bioactivity has been reported in the literature in many cases due to the higher 
lipophilicity of potential drugs.[Showell, G. A.; Mills, J. S. Drug Discovery Today 2003, 8, 
551‒556.; Akama, T.; Ishida, H.; Kimura, U.; Gomi, K.; Saito, H. J. Med. Chem. 1988, 41, 
2056–2067.] However, high lipophilicity often leads to low aqueous solubility, which makes 
administration difficult and might limit the attainment of the proper concentration of the drug 
needed for the desired pharmacological response. In addition, low solubility precludes studies 
in aqueous solution, which are of utmost importance for investigations into the mode of 
action of these compounds. Low aqueous solubility of TSCs is a common feature, that 
explains the limited number of studies in aqueous solution reported so far.43,44,45,46,47 From the 
other side aqueous solubility has influence on a compound’s bioavailability through 
solubility-limited absorption, but is important for validation of in vitro antiproliferative 
activity assays.48  
 
We reported recently on the first proline-TSC hybrids (L- and D-Pro-FTSC) and their 
copper(II) complexes.49 These compounds are highly water-soluble. However, they exhibited 
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only moderate to low cytotoxicity (IC50  100 µM in CH1 cell line for the copper(II) 
complexes, >300 µM for the free ligands), when compared with other HCTs that showed IC50 
values in the nanomolar range.50,51,52 This low cytotoxicity is presumably caused by the very 
low lipophilicity of these compounds, which may hinder cell membrane passage. 
Nevertheless, complex formation with copper(II) had a favorable effect on antiproliferative 
activity. We decided to extend our work and study the effect of other metal ions on 
cytotoxicity of L- and D-Pro-FTSC and that of dimethylation of terminal aminogroup in 
previously reported hybrids and their metal complexes. Dimethylation at terminal nitrogen of 
other HCTs was reported to increase the cytotoxicity.53,54  
 
Herein we report on the synthesis of a new chiral ligand dm-L-Pro-FTSC or (S)-H2L
2, along 
with two optically pure enantiomers L-Pro-FTSC and D-Pro-FTSC reported previously, and 
on six new nickel(II), copper(II) and zinc(II) complexes (13 and 68), in addition to two 
previously reported copper(II) complexes (4 and 5) (Chart 1).  
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Chart 1. L- and D-Pro-FTSC and dm-L-Pro-FTSC and their metal complexes studied in this 
work. Underlined numbers indicate complexes investigated by X-ray diffraction. Co-
crystallized solvent is not included in the formulas (see Experimental section). 
The compounds were characterized by analytical and spectroscopic methods, magnetic 
susceptibility and EPR measurements (1) and X-ray diffraction (13, 6 and 7). Solution 
equilibria of the nickel(II) and zinc(II) complexes formed with L-Pro-FTSC were studied in 
detail by the combination of various methods such as pH-potentiometry, UV−vis and 1H 
NMR spectroscopy in order to determine the stoichiometry and the thermodynamic stability 
of complexes formed in aqueous solution. Complexation of these bivalent metal ions is 
compared to that of copper(II). Finally, the antiproliferative activity and hR2 RNR inhibiting 
activity of new compounds was assayed and discussed.  
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Experimental 
Chemicals. 2,6-Dihydroxymethylpyridine and L-proline methylester hydrochloride were 
purchased from Alfa Aesar, while D-proline methylester hydrochloride from Acros Organics. 
Solvents were dried using standard procedures if needed.55 2-Hydroxymethyl-6-
chloromethylpyridine and 6-chloromethylpyridine-2-carboxaldehyde were synthesized 
according to published procedures.56 KOH and 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) were Sigma-Aldrich and HCl, KCl, NiCl2 and ZnCl2 
were Reanal products. Nickel(II) and zinc(II) stock solutions were prepared by dissolving the 
appropriate amount of the metal chlorides in known amount of HCl and their concentrations 
were determined by complexometry via the EDTA complexes. Accurate strong acid content 
of the metal stock solutions were calculated on the basis of pH-potentiometric titrations. 
 
Synthesis of ligands 
D- and L-Pro-FTSC were synthesized as described elswhere.49  
dm-L-Pro-FTSCH2O0.2EtOH. (S)-1-[(6-Formylpyridin-2-yl)methyl]pyrrolidine-2-carbo-
xylic acid (0.30 g, 1.28 mmol) and 4,4-dimethyl-3-thiosemicarbazide (0.15 g, 1.28 mmol) 
were dissolved in dry ethanol (6 mL) and the reaction mixture was stirred at room 
temperature for 24 h. The white precipitate formed was filtered off under inert atmosphere, 
washed with dry ethanol and dried in vacuo. Yield: 0.17 g, 39%. Anal. Calcd for 
C15H21N5O2S∙H2O∙0.2C2H5OH (M = 362.65 g/mol): C, 51.00; H, 6.73; N, 19.31; S, 8.84. 
Found: C, 50.84; H, 6.56; N, 19.01; S, 8.68. E-isomer: 1H NMR (500 MHz, DMSO-d6) δ 
11.20 (s, 1H, H2), 8.21 (s, 1H, H13), 7.88 – 7.77 (m, 2H, H5, H6), 7.45 (d, J = 7.0 Hz, 1H, H4), 
4.16 (d, J = 14.2 Hz, 1H, H7), 3.90 (d, J = 14.2 Hz, 1H, H7), 3.49 (dd, J = 8.9, 5.3 Hz, 1H, 
H8), 3.13 – 3.06 (m, 1H, H11), 2.66 – 2.58 (m, 1H, H11), 2.19 – 2.05 (m, 1H, H9), 1.96 – 1.67 
(m, 3H, H9, H11). 13C NMR (126 MHz, DMSO-d6) δ 181.06 (Cq, C
14), 173.76 (Cq, C12), 
157.59 (Cq, C3), 153.46 (Cq, C1), 144.17 (CH, C13), 137.81 (CH, C5), 123.55 (CH, C4), 
118.64 (CH, C6), 66.23 (CH, C8), 59.13 (CH2, C
7), 53.54 (CH2, C
11), 42.76 (2CH3, C
15, C16), 
29.28 (CH2, C
9), 23.71,(CH2, C
10). Z-isomer: 1H NMR (500 MHz, DMSO-d6) δ 14.75 (s, 1H, 
H2), 8.05 (t, J = 7.8 Hz, 1H, H5), 7.62 (m, 2H, H4, H6), 7.58 (s, 1H, H13), 4.10 (d, J = 14.1 Hz, 
1H, H7), 3.79 (d, J = 14.0 Hz, 1H, H7), 3.51 – 3.42 (m, 1H, H8), 2.96 – 2.90 (m, 1H, H11), 
2.56 – 2.43 (m, 1H, H11, overlapped with residual DMSO signal), 2.19 – 2.05 (m, 1H, H9), 
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1.96 – 1.67 (m, 3H, H9, H10). 13C NMR (126 MHz, DMSO-d6) δ 180.61 (Cq, C
14), 174.92 
(Cq, C12), 158.33 (Cp, C3), 151.60 (Cq, C
1), 139.26 (CH, C5), 136.65, (CH, C13), 124.96 (CH, 
C6), 124.03 (CH, C4), 65.29 (CH, C8), 59.41 (CH2, C
7), 53.32 (CH2, C
11), 40.61 (2CH3, C
15, 
C16, overlapped with residual DMSO signal), 29.33 (CH2, C
9), 23.43 (CH2, C
10). For atom 
numbering and structures of E and Z isomers see Figure S2. Solubility in water:  413 
mg/mL. ESI-MS (methanol), positive: m/z 336 ([M + H]+). IR (ATR, selected bands, νmax): 
3156, 2963, 1643, 1579, 1547, 1517, 1445, 1346, 1266, 1080, 831, 683, 592 cm–1.  
 
Synthesis of metal complexes  
[Ni(L-Pro-FTSC2H)]22H2OMeOH (12H2OMeOH). To a solution of L-Pro-FTSC (0.10 
g, 0.33 mmol) in water (15 mL) was added a solution of nickel(II) acetate tetrahydrate (0.16 
g, 0.66 mmol) in water (5 mL). The mixture was heated at 70 °C for 1 h and then stirred at 
room temperature overnight. The resulted brown solution of the raw product in water was 
subjected to preparative HPLC (MeOH/H2O). Slow diffusion of diethyl ether into a 
methanolic solution of the purified product gave brown crystals which were filtered off, 
washed with a diethyl ether/methanol 5 : 1 mixture and dried in vacuo. Yield: 0.07 g, 54%. 
Anal. Calcd for C26H30Ni2N10O4S2∙2H2O∙CH3OH (M = 796.17 g/mol): C, 40.73; H, 4.81; N, 
17.59; S, 8.05. Found: C, 40.49; H, 4.51; N, 17.35; S, 7.77. Solubility in water: ≥ 10.3 
mg/mL. ESI-MS (methanol), positive: m/z 364 ([½M + H]+), 386 ([½M + Na)]+). IR (ATR, 
selected bands, νmax): 3294, 1588, 1459, 1162, 785, 668, 605 cm
–1.  
[Ni(D-Pro-FTSC2H)]23.7H2OMeOH (23.7H2OMeOH). To a solution of D-Pro-FTSC 
(0.17 g, 0.55 mmol) in water (30 mL) was added a solution of nickel(II) acetate tetrahydrate 
(0.28 g, 1.11 mmol) in water (10 mL). The mixture was heated at 70 °C for 1 h and then 
stirred at room temperature overnight. The resulted brown solution of the raw product in 
water was subjected to preparative HPLC (MeOH/H2O). Slow diffusion of diethyl ether into 
a methanolic solution of the purified product gave brown crystals which were filtered off, 
washed with a diethyl ether/methanol 5 : 1 mixture and dried in vacuo. Yield: 0.13 g, 65%. 
Anal. Calcd for C26H30Ni2N10O4S2∙3.7H2O∙CH3OH (M = 826.78 g/mol): C, 39.22; H, 5.04; 
N, 16.94; S, 7.75. Found: C, 39.00; H, 4.65; N, 17.08; S, 7.37. Solubility in water: ≥ 10.3 
mg/mL. ESI-MS (methanol), positive: m/z 364 ([½M + H]+), 386 ([½M + Na)]+). IR (ATR, 
selected bands, νmax): 3294, 1588, 1459, 1162, 785, 668, 605 cm
–1.  
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[Ni(dm-L-Pro-FTSC2H)]20.2H2O3.6MeOH (30.2H2O3.6MeOH). (S)-1-[(6-Formyl-
pyridin-2-yl)methyl]pyrrolidine-2-carboxylic acid (0.19 g, 0.81 mmol), 4,4-dimethyl-3-
thiosemicarbazide (0.10 g, 0.81 mmol) and nickel(II) acetate tetrahydrate (0.21 g, 0.86 mmol) 
were dissolved in dry ethanol (12 mL) in a 25 mL Schlenk tube. The mixture was stirred at 
70 °C overnight. The next day a grey precipitate of [Ni(4,4-dimethyl-3-thiosemicarbazide)2] 
was filtered off. The filtrate was subjected to preparative HPLC (MeOH/H2O). Slow 
diffusion of diethyl ether into a methanolic solution of the purified product gave dark brown 
crystals which were filtered off, washed with a diethyl ether/methanol 5 : 1 mixture and dried 
in vacuo. Yield: 0.09 g, 27%. Anal. Calcd for C30H38Ni2N10O4S2∙0.2H2O∙3.6CH3OH (M = 
903.16 g/mol): C, 44.69; H, 5.89; N, 15.51; S, 7.10. Found: C, 44, 35; H, 5.65; N, 15.85; S, 
6.79. Solubility in water: ≥ 15.3 mg/mL. ESI-MS (methanol), positive: m/z 392 ([½M + H]+). 
IR (ATR, selected bands, νmax): 3384, 2922, 1593, 1507, 1362, 1253, 1129, 909, 805, 677 
cm–1. 
Complexes [Cu(L-Pro-FTSC2H)] (4) and [Cu(D-Pro-FTSC2H)] (5) were prepared by 
following a recently published protocol.49 
[Cu(dm-L-Pro-FTSC2H)]H2O0.2MeOH (6H2O0.2MeOH). (S)-1-[(6-Formylpyridin-2-
yl)methyl]pyrrolidine-2-carboxylic acid (0.30 g, 1.28 mmol), 4,4-dimethyl-3-
thiosemicarbazide (0.15 g, 1.28 mmol) and copper(II) acetate monohydrate (0.27 g, 1.36 
mmol) were dissolved in dry ethanol (10 mL) in a 50 mL Schlenk tube. The mixture was 
stirred at 70 °C overnight. The resulted green solution of the raw product in water was 
subjected to preparative HPLC (MeOH/H2O). Slow diffusion of diethyl ether into a 
methanolic solution of the purified product gave green crystals which were filtered off, 
washed with a diethyl ether/methanol 5 : 1 mixture and dried in vacuo. Yield: 0.19 g, 38%. 
Anal. Calcd for C15H19CuN5O2S∙H2O∙0.2CH3OH (M = 421.38 g/mol): C, 43.32; H, 5.21; N, 
16.62; S, 7.60. Found: C, 43.46; H, 5.00; N, 16.46; S, 7.54. Solubility in water: ≥ 8.5 mg/mL. 
ESI-MS (methanol), positive: m/z 795 ([2M + H]+), 817 ([2M+Na)]+). IR (ATR, selected 
bands, νmax): 3542, 3152, 2923, 1596, 1503, 1361, 1247, 1131, 910, 792, 625 cm
–1. 
[Zn(L-Pro-FTSC2H)]1.9H2O (71.9H2O). To a solution of L-Pro-FTSC (0.12 g, 0.39 
mmol) in water (15 mL) was added a solution of zinc(II) acetate dihydrate (0.17 g, 0.78 
mmol) in water (5 mL). The mixture was heated at 70 °C for 1 h. After cooling down the 
solution was concentrated under reduced pressure to about 5 mL and allowed to stand at 4 °C 
overnight. Yellow, needle-like crystals were filtered off, washed with cold water and dried in 
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vacuo. Yield: 0.13 g, 65%. Anal. Calcd for C13H15N5O2SZn∙1.9H2O (M = 404.98 g/mol): 
C, 38.56; H, 4.68; N, 17.29; S, 7.92%. Found: C, 38.75; H, 4.29; N, 16.98; S, 8.04%. 
1H NMR (500 MHz, DMSO-d6) δ 8.22 (s, 1H, H
12), 8.08 (t, J = 7.7 Hz, 1H, H4), 7.62 (d, 
J = 7.5 Hz, 1H, H5), 7.57 (s, 2H, H3‘), 7.42 (d, J = 7.6 Hz, 1H, H3), 4.34 (d, J = 16.8 Hz, 1H, 
H6), 4.08 (d, J = 16.9 Hz, 1H, H6), 3.50 (m, 1H, H10), 3.25 – 3.12 (m, 1H, H7), 2.99 – 2.86 
(m, 1H, H10), 2.32 (m, 1H, H8), 1.95 (m, 1H, H9), 1.79 (m, 2H, H8, H9) ppm. 13C NMR 
(125 MHz, DMSO-d6) δ 183.96 (Cq, C
13), 177.11 (Cq, C11), 156.16 (Cq, C1), 149.78 (Cq, 
C2), 143.04 (CH, C4), 135.15 (CH, C12), 123.05 (CH, C3), 123.01 (CH, C5), 72.48 (CH, C7), 
60.82 (CH2, C
6), 58.57 (CH2, C
10), 31.38 (CH2, C
8), 24.98 (CH2, C
9) ppm. Solubility in 
water: ≥ 1.4 mg/mL. ESI-MS (methanol), positive: m/z 370 ([M + H]+), 392 ([M + Na)]+). IR 
(ATR, selected bands, νmax): 3287, 1596, 1454, 1155, 1076, 1009, 904, 781, 656, 605 cm
–1.  
[Zn(D-Pro-FTSC2H)]2.6H2O (82.6H2O). To a solution of D-Pro-FTSC (0.15 g, 0.49 
mmol) in water (20 mL) was added a solution of zinc(II) acetate dihydrate (0.22 g, 0.98 
mmol) in water (5 mL). The mixture was heated at 70 °C for 1 h. After cooling down the 
solution was concentrated under reduced pressure to about 5 mL and allowed to stand at 4 °C 
overnight. Yellow, needle-like crystals were filtered off, washed with cold water and dried in 
vacuo. Yield: 0.06 g, 33%. Anal. Calcd for C13H15N5O2SZn∙2.6H2O (M = 417.59 g/mol): C, 
37.39; H, 4.88; N, 16.77; S, 7.68. Found: C, 37.64; H, 4.87; N, 16.41; S, 7.30. 1H NMR 
(500 MHz, DMSO-d6) δ 8.22 (s, 1H, H
12), 8.08 (t, J = 7.7 Hz, 1H, H4), 7.62 (d, J = 7.5 Hz, 
1H, H5), 7.57 (s, 2H, H3‘), 7.42 (d, J = 7.6 Hz, 1H, H3), 4.34 (d, J = 16.8 Hz, 1H, H6), 4.08 (d, 
J = 16.9 Hz, 1H, H6), 3.50 (m, 1H, H10), 3.25 – 3.12 (m, 1H, H7), 2.99 – 2.86 (m, 1H, H10), 
2.32 (m, 1H, H8), 1.95 (m, 1H, H9), 1.79 (m, 2H, H8, H9) ppm. 13C NMR (125 MHz, DMSO-
d6) δ 183.96 (Cq, C
13), 177.11 (Cq, C11), 156.16 (Cq, C1), 149.78 (Cq, C2), 143.04 (CH, C4), 
135.15 (CH, C12), 123.05 (CH, C3), 123.01 (CH, C5), 72.48 (CH, C7), 60.82 (CH2, C
6), 58.57 
(CH2, C
10), 31.38 (CH2, C
8), 24.98 (CH2, C
9) ppm. Solubility in water: ≥ 1.4 mg/mL. ESI-MS 
(methanol), positive: m/z 370 ([M + H]+), 392 ([M + Na)]+). IR (ATR, selected bands, νmax): 
3287, 1596, 1454, 1155, 1076, 1009, 904, 781, 656, 605 cm–1.  
 
pH-potentiometric measurements. The exact concentration of the stock solutions of the L-
Pro-FTSC was determined from pH-potentiometric titrations by using the computer program 
HYPERQUAD.57 The pH-metric measurements for the determination of the proton dissociation 
constants of the L-Pro-FTSC and the overall stability constants of the metal complexes were 
carried out at 298.0 ± 0.1 K in water and at an ionic strength of 0.10 M KCl to keep the 
 11
activity coefficients constant. The titrations were performed with carbonate-free KOH 
solution of known concentration (0.10 M). The concentrations of the base and the HCl were 
determined by pH-potentiometric titrations. An Orion 710A pH-meter equipped with a 
Metrohm combined electrode (type 6.0234.100) and a Metrohm 665 Dosimat burette were 
used for the titrations. The electrode system was calibrated to the pH = −log[H+] scale 
according to the method suggested by Irving et al.58 The average water ionization constant, 
pKw, is 13.76 ± 0.01, which corresponds well to the literature data.
59 The reproducibility of 
the titration points included in the calculations was within 0.005 pH. The pH-metric titrations 
were performed in the pH range 2.0 − 11.5. The initial volume of the samples was 5.0 mL. 
The ligand concentration was 2 mM and metal ion-to-ligand ratios of 1:1 − 1:4 were used. 
The accepted fitting of the titration curves was always less than 0.01 mL. Samples were 
deoxygenated by bubbling purified argon through them for approximately 10 min prior to the 
measurements. Argon was also passed over the solutions during the titrations. 
 
The protonation constants of the L-Pro-FTSC were determined with the computer program 
HYPERQUAD.57 PSEQUAD60 was utilized to establish the stoichiometry of the complexes and to 
calculate the stability constants (log(MpLqHr)). (MpLqHr) is defined for the general 
equilibrium pM + qL + rH  MpLqHr as (MpLqHr) = [MpLqHr]/[M]
p[L]q[H]r, where M 
denotes the metal ion and L the completely deprotonated ligand. In all calculations 
exclusively titration data were used from experiments in which no precipitate was visible in 
the reaction mixture. 
 
UV–vis spectrophotometric, CD and 1H NMR measurements. A Hewlett Packard 8452A 
diode array spectrophotometer was used to record the UV–vis spectra in the 200 to 800 nm 
window. The path length was 0.5 or 1.0 cm. The spectrophotometric titrations were 
performed on samples of the L-Pro-FTSC alone or with nickel(II) ions; the concentration of 
the ligand was ~100 µM and the metal-to-ligand ratios were 1:1 and 1:2 over the pH range 
between 2 and 11.5 at an ionic strength of 0.10 M (KCl) in water at 298.0 ± 0.1 K. 
Measurements for the nickel(II) − L-Pro-FTSC systems at metal-to-ligand ratio 1:1 were also 
carried out at various concentrations (1 M – 0.8 mM) and at pH 7.4 (20 mM HEPES buffer).  
 
One dimensional 1H and 13C NMR and two dimensional 1H-1H COSY, 1H-1H TOCSY, 1H-1H 
TOCSY, 1H-1H ROESY or 1H-1H NOESY, 1H-13C HSQC and 1H-13C HMBC NMR spectra 
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were recorded on two Bruker Avance III instruments. DMSO-d6 or CDCl3 were used as 
solvent. 1H or 13C chemical shifts were measured relatively to the residual solvent peaks. The 
pH-dependent 1H NMR studies were carried out on a Bruker Ultrashield 500 Plus instrument. 
4,4-Dimethyl-4-silapentane-1-sulfonic acid was used as an internal NMR standard and 
WATERGATE method was used to suppress the solvent resonance. L-Pro-FTSC was dissolved 
in a 10% (v/v) D2O/H2O mixture in a concentration of 1 mM, the zinc(II)-to-ligand ratios 
were 1:1 and 1:2 and the nickel(II)-to-ligand ratio was 1:1 at 298 K. PSEQUAD60 was used to 
calculate the pK value of the complex [ZnLH]+. 1H NMR spectra were recorded for the 
zinc(II) − L-Pro-FTSC (1:1) system at 1 mM concentration in the presence of 630 M HSA at 
pH 7.40 (20 mM HEPES buffer, 0.1 M KCl) or in MEM at 298 K after 24 h incubation.  
 
CD spectra for the nickel(II) and zinc(II) complexes of L-Pro-FTSC and D-Pro-FTSC were 
recorded on a Jasco J-815 spectrometer in the wavelength interval from 230 to 600 nm. 
Samples contained 0.500 mM nickel(II) or 0.025 mM zinc(II) complex at pH 7.4 (20 mM 
HEPES buffer, 0.1 M KCl) using optical cells of 0.2 or 0.5 cm path lengths, respectively. CD 
data are given as the differences in molar absorptivities between left and right circularly 
polarized light, based on the concentration of the ligand (Δε = ΔA / l/ cligand or complex). 
 
Determination of the distribution coefficient (D). D7.4 values of the zinc(II) and nickel(II) 
complexes of L- and D-Pro-FTSC, as well as of dm-L-Pro-FTSC (3, 68) were determined by 
the traditional shake-flask method in n-octanol/buffered aqueous solution at pH 7.4 (20 mM 
HEPES buffer) at 298.0 ± 0.2 K as described previously,49 and compared to those of metal-
free hybrids. Two parallel experiments were performed for each sample. The complexes were 
dissolved in 0.1 mM in the n-octanol pre-saturated aqueous solution of the buffer at constant 
ionic strength (0.10 M KCl). The aqueous solutions and n-octanol with 1:1 phase ratio were 
gently mixed with 360° vertical rotation for 3 h to avoid the emulsion formation, and the 
mixtures were centrifuged at 5000 rpm for 3 min by a temperature controlled centrifuge 
(Sanyo) at 298 K. After separation UV−vis spectra of the complexes in the aqueous phase 
were compared to those of the original aqueous solutions. D7.4 values of the metal complexes 
were calculated as the mean of [Absorbance (original solution) / Absorbance (aqueous phase 
after separation) – 1] obtained at the lmax values (360 nm for the zinc(II), 375 or 380 nm for 
the nickel(II) and 396 nm for the copper(II) complexes). When no measurable amount of the 
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complexes was found in the n-octanol phase, D7.4 values for those compounds were merely 
estimated.  
Crystallographic Structure Determination. X-ray diffraction measurements were 
performed on Bruker X8 APEXII CCD and Bruker D8 VENTURE diffractometers. Single 
crystals were positioned at 40, 35, 100, 35 and 40 mm from the detector, and 561, 772, 2147, 
2797 and 815 frames were measured, each for 100, 4, 24, 4 and 30 s over 1, 0.4, 0.4, 0.4 and 
1° scan width for 1∙3.25CH3OH, 2∙4CH3OH, 3∙2.88CH3OH, 6∙H2O and 7∙CH3OH, 
correspondingly. The data were processed using SAINT software.61 Crystal data, data 
collection parameters, and structure refinement details are given in Table 1. The structures 
were solved by direct methods and refined by full-matrix least-squares techniques. Non-H 
atoms were refined with anisotropic displacement parameters. H atoms were inserted in 
calculated positions and refined with a riding model. Co-crystallized methanol in 
3∙2.88CH3OH was found in part disordered. The disorder was solved by using SADI 
instructions implemented in SHELXL-97, while the atoms involved were refined with 
isotropic displacement parameters and the positions of H atoms were not calculated. One 
methanol molecule from two crystallographically independent in the structure of 7∙CH3OH 
was found disordered over two positions with s.o.f. 0.6 : 0.4. The following computer 
programs were used: structure solution, SHELXS-97 and refinement, SHELXL-97;62 
molecular diagrams, ORTEP.63  
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Table 1. Crystal data and details of data collection for 13.25CH3OH, 24CH3OH, 32.88CH3OH, 6H2O and 7CH3OH. 
 13.25CH3OH 24CH3OH 32.88CH3OH 6H2O 7CH3OH 
empirical formula  C29.25H43.5N10Ni2O7.75S2 C30H46N10Ni2O8S2 C32.88H49.5N10Ni2O6.88S2 C15H21CuN5O3S C14H19N5O3SZn 
Fw 840.78 856.31 677.09 414.97 725.05 
space group P212121 P212121 P212121 P212121 P21 
A [Å] 13.1049(7) 13.2489(4) 11.7885(13) 6.6987(7) 8.2454(4) 
B [Å] 15.1240(13) 15.2821(5) 11.8487(13) 13.3713(18) 11.8012(6) 
C [Å] 18.0808(16) 17.9458(7) 55.473(6) 18.755(2) 16.8293(7) 
 [°]      
 [°]     93.338(3) 
 [°]      
V [Å3] 3583.6(5) 3633.5(2) 7748.4(15) 1679.9(4) 1634.81(13) 
Z 4 4 8 4 4 
l [Å] 0.71073 0.71073 0.71073 0.71073 0.71073 
calcd [g cm
-3] 1.558 1.565 1.502 1.641 1.636 
crystal size, mm 0.10  0.02  0.01 0.22  0.18  0.11 0.37  0.28  0.05 0.46  0.25  0.23 0.07  0.07  0.04 
T [K] 120(2) 100(2) 100(2) 100(2) 120(2) 
 [mm-1] 1.230 1.215 1.139 1.451 1.654 
R1
[a] 0.0603 0.0316 0.0405 0.0189 0.0408 
wR2
[b] 0.1373 0.0661 0.1081 0.0522 0.0647 
GOF[c] 1.010 1.034 1.092 1.010 1.019 
Flack parameter 0.04(2) 0.001(7) 0.03(1) 0.009(6) 0.008(9) 
a R1 = ||Fo|  |Fc||/|Fo|. 
b wR2 = {[w(Fo
2  Fc
2)2]/[w(Fo
2)2]}1/2. c GOF = {[w(Fo
2  Fc
2)2]/(n  p)}1/2, where n is the number of 
reflections and p is the total number of parameters refined.  
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Magnetic Measurements and EPR Spectroscopy. Magnetic susceptibility data (2300 K) were 
collected on powdered samples using a SQUID magnetometer (Quantum Design MPMS-XL) at 
0.1 T. The temperature dependence of the magnetic susceptibility for dinuclear nickel(II) cluster 
1 was analyzed according to the Hamiltonian (eq 1),64  
Ĥ = 2J Ŝ1·Ŝ2 + BB {g1} Ŝ1 + Ŝ1 {D1} Ŝ1 + BB {g2} Ŝ2 + Ŝ2 {D2} Ŝ2 + Ŝ1 {D12} Ŝ2      (1),  
in which {g1} and {g2} represent the local g matrices, {D1} and {D2} are the local single-ion zfs 
tensors and the {D12} term contains the magnetic dipolar interactions along with the anisotropic 
exchange interactions between the metal ions. The more commonly used zfs parameters D and E 
are related to the tensor components by eq 2: 
D = (2Dzz  Dxx  Dyy) / 2,              E = (Dxx  Dyy) / 2                   (2) 
These formulas are valid for each of the {D} quantities in eq 1. 
To obtain a manageable model it was assumed that the two Ni ions are equivalent, which is not 
strictly correct. Different orientation of the {D1} and {D2} tensors was taken into account, as the 
Z axes of the two D tensors are tilted by 26 deg from each other according to the DFT 
calculations (see the DFT section below), but the corresponding components of {D1} and {D2} 
were assumed equal. These {D} tensor components were not fitted but were calculated from the 
D and E values in the S = 2 state found from EPR (below). The spin Hamiltonian matrix was 
diagonalised to find the energy levels and the magnetic susceptibility per mole of dimer was 
calculated from eq 3: 


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The derivatives Ei/B were evaluated numerically by calculating the energy levels slightly 
below and slightly above (±5 Gauss) the operational magnetic field of a SQUID magnetometer 
(1000 G in our case). 
The terms {D1} and {D2} represents the usual Zero-Field Splitting (ZFS) of the 
3A2 ground state 
of Ni(II).65  
This and similar models have been widely used to characterize magnetic interaction in different 
dinuclear nickel(II) complexes.65,66,67 We also allowed an interdimer exchange term (zJ’) in the 
molecular field approximation68 according to the eq. 4: 

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BNg
zJ
         (4) 
The X-band (9.5 GHz) EPR spectra were recorded at 20 K on a Bruker Elexsys-II EPR 
spectrometer with an Oxford Instruments ESR900 helium cryostat under the following 
conditions: microwave power 3.2 mW, modulation amplitude 5 G, modulation frequency 100 
kHz, conversion time 29.3 ms. The concentration of the tyrosyl radical was determined by 
double integration of EPR spectra recorded at nonsaturating microwave power levels, and 
compared with the copper standard (1 mM CuSO4 in 10 mM EDTA). The calculated radical 
concentration was normalized and expressed in percent of the control sample. High-field, high-
frequency EPR spectra at temperatures ranging from ca. 3 to 10 K were recorded on a home-built 
spectrometer at the EMR facility of the NHMFL.69 The instrument is a transmission-type device 
in which microwaves are propagated in cylindrical lightpipes. The microwaves were generated 
by a phase-locked Virginia Diodes source generating frequency of 13 ± 1 GHz which was 
multiplied by a cascade of frequency doublers and/or triplers. A superconducting magnet 
(Oxford Instruments) capable of reaching a field of 17 T was employed. 
 
17 
 
We simulated EPR spectra of 1 using the “giant spin” approach, in which the spectra of the 
coupled states (S = 1 and S = 2) were analyzed separately in terms of the coupled-spin 
Hamiltonian (eq 5): 
ĤS = BB·{gS}·Ŝ + D[Ŝz
2 – S(S+1)/3] + E(Ŝx
2 – Ŝy
2 )                   (5), 
in which each of the spin states has its own zero-field splitting parameters D, E and g matrices 
which can be related to the single-ion parameters64,70 corresponding to the spin Hamiltonian (1). 
 
Cell lines and culture conditions. Human cervical carcinoma (HeLa), human melanoma 
(FemX), human alveolar basal adenocarcinoma (A549), human breast cancer  (MDA-MB-453) 
cell lines and normal human fetal lung fibroblast cell line (MRC-5) were maintained as 
monolayer culture in the Roswell Park Memorial Institute (RPMI) 1640 nutrient medium (Sigma 
Chemicals Co, USA). RPMI 1640 nutrient medium was prepared in sterile deionized water, 
supplemented with penicillin (192 U/mL), streptomycin (200 mg/mL), 4-(2-hydroxyethyl) 
piperazine-1-ethanesulfonic acid (HEPES) (25 mM), L-glutamine (3 mM) and 10% of heat-
inactivated foetal calf serum (FCS) (pH 7.2). The cells were grown at 37 ºC in 5% CO2 in a 
humidified air atmosphere.  
MTT assay. Antiproliferative activity of the investigated compounds was determined using 3-
(4,5-dymethylthiazol-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) assay.71 Cells 
were seeded into 96-well cell culture plates (Thermo Scientific Nunc™), at a cell density of 3000 
c/w (HeLa), 6000 c/w (A549), 4000 c/w (MDA-MD-453), 5000 c/w (FemX, MRC-5) in 100 µl 
of culture medium. After 24 h of growth, cells were exposed to the serial dilutions of the tested 
complexes. The investigated compounds were dissolved in DMSO at a concentration of 30 mM 
as stock solution, and prior the use diluted with nutrient medium to the desired final 
concentrations (in range from 18.75 up to 300 µM). Each concentration was tested in triplicates. 
Serial dilutions were made in culture medium so that the final concentration of DMSO per well 
was less than 1% (v/v) in all experiments. After incubation periods of 48 h, 20 L of MTT 
solution (5 mg/mL in phosphate buffer solution, pH 7.2) were added to each well. Samples were 
incubated for 4 h at 310 K, with 5% CO2 in a humidified atmosphere. Formazan crystals were 
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dissolved in 100 L of 10% sodium dodecyl sulfate (SDS). Absorbances were recorded after 24 
h, on an enzyme-linked immunosorbent assay (ELISA) reader (ThermoLabsystems Multiskan 
EX 200–240 V), at the wavelength of 570 nm. IC50 values (M), were determined from the cell 
survival diagrams. The percentages of surviving cells relative to untreated controls were 
determined. The IC50 value, defined as the concentration of the compound causing 50% cell 
growth inhibition, was estimated from the dose-response curves. 
  
Ribonucleotiode reductase inhibition 
Sample preparation for EPR measurements. The tyrosyl radical reduction kinetics in human 
R2 RNR protein (hR2) by L-Pro-FTSC and dm-L-Pro-FTSC, as well as complexes 4, 6, and 7, 
was monitored by EPR spectroscopy. Purified recombinant hR2 was obtained from the 
Department of Medical Biochemistry and Biophysics, Karolinska Institute, Sweden. The iron-
reconstituted R2 protein contained 2 iron ions and 0.38 tyrosyl radicals per polypeptide. Samples 
containing 20 μM hR2 in Tris buffer, pH 7.60 / 100 mM KCl / 5% glycerol, 20 μM compound 
(1% (w/w) DMSO/H2O), and 2 mM dithiothreitol (DTT) (only for experiments done in the 
presence of the reductant) were incubated at room temperature for designated times and quickly 
frozen in cold isopentane. The same sample was used for repeated incubations and was refrozen 
before each EPR measurement. The intrinsic decay of the tyrosyl radical, obtained from the 
control sample containing 20 μM hR2 in Tris buffer, pH 7.60 / 100 mM KCl / 5% glycerol, was 
subtracted at each time point.  
 
Results and Discussion 
Synthesis and Characterization of dm-L-Pro-FTSC. dm-L-Pro-FTSC was synthesized in six 
steps as shown in Scheme S1. The first five steps to the key-aldehyde F were described in detail 
previously.49 Aldehyde F was then condensed in a Schiff-base reaction with 4,4-dimethyl-3-
thiosemicarbazide in dry ethanol at room temperature. One dimensional 1H and 13C NMR and 
two dimensional 1H-1H COSY, 1H-1H TOCSY, 1H-1H NOESY, 1H-13C HSQC and 1H-13C 
HMBC NMR spectra were in agreement with the expected structure, enabling the assignment of 
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all 1H and 13C resonances (for atom numbering see Scheme S2 in the Supporting Information). 
dm-L-Pro-FTSC exists as a mixture of E and Z isomers in DMSO with a E : Z ratio of 1 : 0.39. 
The proton at the hydrazinic nitrogen N2, in the Z configuration is involved in a hydrogen bond 
to the pyridine nitrogen leading to a strong downfield shift of its resonance signal from 11.20 to 
14.75 ppm. The solvent dependent formation of E and Z isomers is well documented in the 
literature and our data is in good agreement with that reported for other α-pyridyl-TSCs.72 The 
purity of the compound was further confirmed by elemental analysis. The ESI mass spectra 
recorded in a positive ion mode showed a strong peak at m/z 336 due to the [M + H]+ ion. 
Synthesis and Characterization of the Metal(II) Complexes. The zinc(II) and nickel(II) 
complexes of D- and L-Pro-FTSC were prepared similarly to the previously reported copper(II) 
complexes, by reaction of the metal(II) acetate hydrates with the ligand in aqueous solution. The 
nickel(II) and copper(II) complexes of dm-L-Pro-FTSC were prepared in situ by reaction of  the 
aldehyde F with 4,4-dimethyl-3-thiosemicarbazide in the presence of the corresponding metal(II) 
acetate in dry ethanol. The structure of all metal(II) complexes (except [Zn(D-Pro-FTSC2H)]) 
in the solid state was confirmed by single crystal X-ray diffraction. ESI-MS spectra of 1 and 2 
recorded in a positive ion mode showed peaks at m/z 364 and 386 attributed to [Ni(L-Pro-
FTSC2H) + H]+ or [Ni(D-Pro-FTSC2H) + H]+ and to [Ni(L-Pro-FTSC2H) + Na]+ or [Ni(D-
Pro-FTSC2H) + Na]+, respectively, while that of 3 at m/z 392 due to [Ni(dm-L-Pro-FTSC2H) 
+ H]+. Strong signals at m/z 795 and 817 in the mass spectrum of 6 were assigned to [{Cu(dm-L-
Pro-FTSC2H)}2 + H]
+ and [{Cu(dm-L-Pro-FTSC2H)}2 + Na]
+, respectively, while those at 
m/z 370 and 392 in mass spectra of 7 and 8 to [M + H]+ and [M + Na]+ ions, respectively. The 
purity of the compounds was confirmed by elemental analyses. Circular dichroism (CD) spectra 
recorded for the aqueous solutions of nickel(II) and zinc(II) complexes of L-Pro-FTSC and D-
Pro-FTSC (1, 2 and 7, 8) at physiological pH reveal that all of them are optically active and show 
Cotton effects (see Figure S1 and S2 in the Supporting Information). As expected, they are 
mirror images over the 230−350 nm region of the CD spectra, while their UV−vis spectra are 
identical. 
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X-ray Crystallography. The results of X-ray diffraction studies of 1−3, 6 and 7 are shown in 
Figure S3 (see Supporting Information) and Figures 14. The complexes 1−3 and 6 crystallized 
in the noncentrosymmetric orthorhombic space group P212121, while 7 in the 
noncentrosymmetric monoclinic space group P21. The proline-thiosemicarbazone hybrids L-Pro-
FTSC, D-Pro-FTSC and/or dm-L-Pro-FTSC in 1−3 and 6, 7 act as pentadentate doubly-
deprotonated ligands binding to nickel(II), copper(II) or zinc(II) via pyridine nitrogen atom, 
imine nitrogen, thiolato S atom, tertiary proline nitrogen, and proline carboxylato oxygen atom. 
While in copper(II) and zinc(II) complexes 6 and 7 (Figures 3 and 4) the coordination number 
(CN) of the central metal ion is 5, and the coordination polyhedron can be described as a square-
pyramid ( = 0.09 and 0.07, respectively),73 the CN of the nickel(II) in compounds 1−3 is 
increased to 6 by coordination of an adjacent Ni(L-Pro-FTSC2H), Ni(D-Pro-FTSC2H) or 
Ni(dm-L-Pro-FTSC2H) complex via thiolato S atom, which acts as a bridging ligand between 
two nickel(II) ions associating the two monomeric complexes in a dimer (Figures S3, 1 and 2). 
One precedence of a related thiolato-bridged dimer with a central Ni(µ-S)2Ni core, in which each 
nickel(II) atom is surrounded by O, N, S donor atoms of a tridentate doubly deprotonated 5-
nitrobenzaldehyde 4N-methylthiosemicarbazone (H2L), and two nitrogen atoms of a bipyridine 
coligand, characterized by X-ray diffraction, has been found in CSD data base.74 Upon 
coordination of L-prolinate moiety to metal ion via the nitrogen atom, the latter, in addition to 
C12 (or C14 in 3 and 6), becomes a chiral center. In contrast to the literature reports,75 where in 
most cases the nitrogen atom adopts the same configuration as the asymmetric prolinate carbon 
(SCSN or RCRN), in complexes 1−3, 6 and 7 the nitrogen and the asymmetric carbon of the proline 
moiety adopt opposite configurations by coordination to metal (SCRN or RCSN). Documented 
opposite configurations resulted from coordination to metal ion or protonation of the proline 
nitrogen atom are rare.76 Of note is the formation of four five-membered chelate cycles upon 
coordination of the ligand to metal ion. Three of these are essentially planar, while the fourth 
prolinic moiety adopts a half-chair conformation.  
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Figure 1. ORTEP view of 2 with thermal displacement ellipsoids drawn at the 50% probability 
level. Selected bond distances (Å) and bond angles (deg): Ni1−N1 1.9944(17), Ni1−N2 
2.0515(17), Ni1−N5 2.2247(18),  Ni1−S1 2.3946(5), Ni1−S2 2.4995(5), Ni1−O1 2.0766(15), 
N2−N3 1.363(2), C7−S1 1.762(2); N1−Ni1−N2 78.71(7), N1−Ni1−N5 78.08(7), N5−Ni1−O1 
81.40(6), N1−Ni1−O1 87.41(6), N2−Ni1−O1 88.37(6), S1−Ni1−O1 96.00(4), S1−Ni1−S2 
86.845(18), Ni1−S1−Ni2 92.065(18), Ni1−S2−Ni2 92.648(18), Ni2−N6 1.9894(17), Ni2−N7 
2.0496(17), Ni2−N10 2.2107(16),  Ni2−S2 2.4042(5), Ni2−S1 2.5321(6), Ni2−O3 2.0417(14), 
N7−N8 1.367(2), C20−S2 1.770(2); N6−Ni2−N7 78.83(7), N6−Ni2−N10 79.09(7), 
N10−Ni2−O3 81.55(6), N6−Ni2−O3 89.72(6), N7−Ni2−O3 89.52(6), S2−Ni2−O3 93.26(4), 
S1−Ni2−S2 85.905(18). 
 
Figure 2. ORTEP view of 3 with thermal displacement ellipsoids drawn at the 50% probability 
level. Selected bond distances (Å) and bond angles (deg): Ni1−N1 1.975(3), Ni1−N2 2.027(3), 
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Ni1−N5 2.199(4),  Ni1−S1 2.3896(11), Ni1−S2 2.5239(11), Ni1−O1 2.059(3), N2−N3 1.359(5), 
C7−S1 1.766(4); N1−Ni1−N2 79.10(14), N1−Ni1−N5 79.17(14), N5−Ni1−O1 80.98(13), 
N1−Ni1−O1 89.41(13), N2−Ni1−O1 89.49(13), S1−Ni1−O1 95.82(9), S1−Ni1−S2 86.12(4), 
Ni1−S1−Ni2 93.22(4), Ni1−S2−Ni2 93.86(4), Ni2−N6 1.989(3), Ni2−N7 2.038(3), Ni2−N10 
2.198(3),  Ni2−S2 2.3758(11), Ni2−S1 2.5360(11), Ni2−O3 2.032(3), N7−N8 1.355(5), C22−S2 
1.767(4); N6−Ni2−N7 79.08(14), N6−Ni2−N10 79.01(14), N10−Ni2−O3 81.18(12), 
N6−Ni2−O3 91.80(13), N7−Ni2−O3 89.03(12), S2−Ni2−O3 90.76(9), S1−Ni2−S2 86.14(4). 
 
 
 
Figure 3. ORTEP view of 6 with thermal displacement ellipsoids drawn at the 50% probability 
level. Selected bond distances (Å) and bond angles (deg): Cu−N1 1.9335(11), Cu−N2 
1.9887(11), Cu−S 2.2668(4), Cu−N5 2.1343(11), Cu−O1 2.1655(10), N2−N3 1.3511(15), C7−S 
1.7636(13); N1−Cu−N2 80.36(5), N1−Cu−N5 81.75(4), N5−Cu−O1 79.14(4), N1−Cu−O1 
94.63(4), N2−Cu−O1 106.20(4), S−Cu−O1 106.69(3).   
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Figure 4. ORTEP view of 7 with thermal displacement ellipsoids drawn at the 50% probability 
level. Selected bond distances (Å) and bond angles (deg): Zn1a−N1a 2.066(3), Zn1a−N2a 
2.140(3), Zn1a−S1a 2.2913(9), Zn1a−N5a 2.231(3), Zn1a−O1a 1.989(2), N2a−N3a 1.354(4), 
C7a−S1a 1.748(3); N1a−Zn1a−N2a 75.00(12), N1a−Zn1a−N5a 77.48(11), N5a−Zn1a−O1a 
82.97(10), N1a−Zn1a−O1a 99.77(11), N2a−Zn1a−O1 105.14(10), S1a−Zn1a−O1a 107.26(8).   
The complexes are involved in intermolecular hydrogen bonding interactions. In particular, the 
nitrogen atom N4 of one terminal amino group in the dimer 2 acts as a proton donor in hydrogen 
bonds to oxygen atoms O6 and O7 of the two co-crystallized methanol molecules (see Figure 
S4), while the nitrogen atom N9 of the second terminal amino group also forms two hydrogen 
bonds, one to carboxylato oxygen atom O4i, and the second to O8i of the third co-crystallized 
methanol of the adjacent complex. The hydrazinic nitrogen N3, and carboxylate oxygens O1, O2 
and O4 are proton acceptors in strong hydrogen bonds with O8ii, O5ii, O6ii and O7i of the 
neighboring methanol molecules, (atoms marked with i have been generated via symmetry 
transformation x − 0.5, −y + 0.5, −z + 1, while those with ii via symmetry transformation −x + 
0.5, −y + 1, z − 0.5). 
Dimethylation of the terminal amino group reduces strongly the involvement of complexes in 
intermolecular hydrogen bonding interactions, as can be seen in the crystal structures of 3 and 6. 
Detail of H-bonding in 3 is not specified because of severe disorder of co-crystallized methanol 
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molecules in the crystal. The co-crystallized water molecule in 6 acts as a proton donor to 
carboxylato oxygen atom O2i and thiolato atom Sii forming two strong hydrogen bonds (Figure 
S5). Atoms marked with i have been generated via symmetry transformation x + 1, y, z, while 
those with ii via symmetry transformation −x + 0.5, −y + 1, z + 0.5. 
The terminal amino group of both ctystallographically independent molecules A and B of the 
complex [Zn(L-Pro-FTSC)] (7) are involved as proton donors in hydrogen bonding to N3b 
(molecule B) and O2ai (molecule A) and to N3a and O3b, respectively (Figure S6). The 
carboxylato oxygen atoms O2a and O2b act as proton acceptors in hydrogen bonds with O3aii 
and O3bii, which play a role of proton donors. Atoms marked with i, ii and iii have been 
generated via symmetry transformations x + 1, y, z, −x, y + 0.5, −z + 1 and −x + 1, y + 0.5, −z + 
1, respectively. 
Magnetic Properties. The magnetic properties of 1 have been investigated in the temperature 
range 2300 K. At 300 K the T product (at 0.1 T ) is 2.43 cm
3 K mol1 and it increases when 
the temperature is lowered indicating the presence of ferromagnetic exchange interactions in the 
Ni2 dimer (Figure 5). The room temperature magnitude of T imposes the upper limit of 2.2 on 
the g value. The T product increases continuously to reach a maximum of 3.16 cm
3 K mol1 at 
about 20 K (Figure 5), and subsequently drops down to 2.01 cm3 K mol1 at 2 K as a result of 
ZFS or/and intermolecular interactions.  
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Figure 5. Plots of  χMT and χM versus T for 2. The red trace corresponds to the best fit with model 
parameters indicated in the text. 
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The fitting procedure led to J = +10.5(3) cm1, g = 2.13(2), D(ZFS) = +7.8 cm
1  (fixed), E = 2.2 
cm1 (fixed) zJ’ = 0.29 cm1  in reasonable agreement with the experimental data (R = 6 × 
104). When the restrictions on D and E are released, much better fit is possible even without the 
zJ’ term, but the resulting D and E are in disagreement with the EPR data. 
DFT calculations. “Broken-symmetry”77 Density Functional Theory (DFT) calculations were 
performed using the software package ORCA78 to get more insight into the exchange 
interactions. The X-ray coordinates were used in the calculations. The TZVPP function base was 
used for nickel and all coordinated atoms while VDZ functions were used for other atoms.79 The 
B3LYP functional was employed.80  In the “broken symmetry” procedure an SCF calculation is 
first performed on a molecule in the high-spin state (HS), which in our case is an S = 2 state. 
Next, a “broken symmetry” state (BS) is set up in which two unpaired electrons on one nickel(II) 
are spin-up and two electrons on another nickel(II) are spin-down and a second SCF calculation 
is performed. The exchange integral is then evaluated using: J = (EHSEBS)/(<S
2>HS<S
2>BS)). 
J = 15 cm1 was calculated, in a reasonable agreement with the result of the magnetic data fitting. 
 
 
 
 
 
 
Figure 6. Two pairs of the magnetic orbitals of Ni(II) derived from the "broken symmetry" DFT 
calculations. Small overlap integrals (0.0065 and 0.0002 for the upper and lower pair, 
respectively) favor the ferromagnetic exchange. 
 
26 
 
Ferromagnetic interactions in the present dimer are reflected in weak overlap between the 
magnetic orbitals of the two nickel ions. The overlap integrals calculated from DFT for two pairs 
of the magnetic orbitals (Figure 6) are 0.0065 and 0.0002, which favors the ferromagnetic 
exchange. For comparison, in an antiferromagnetic dinuclear Ni(II) complex with J = 78 cm1 
(converted to the notation used in this paper), the overlap integrals of 0.042 and 0.075 were 
found in an analogous calculation.81 
EPR Spectra. Well resolved high-field spectra were observed at frequencies over the range 
50420 GHz at 3 K - the lowest temperature that can be reached on our EPR instrument (Figure 
7). At this temperature the spectra are expected to exhibit mainly transitions within the ground 
quintet state (S = 2). No resonances due to the excited S = 1 state were observed at higher 
temperatures as the spectra quality very quickly deteriorated with the temperature. The highest-
field resonance in the 156 and 222 GHz spectra in Figure 7, which moves beyond the available 
magnetic field at higher frequencies, is the “Z” resonance in the S = 2 state.  
The “giant spin” method requires that the coupled spin states are well separated from each other, 
which is not fulfilled in the present case where the exchange interactions are comparable to the 
zero-field splitting causing their mixing. Simulation of the powder spectra was thus not 
successful, but the observation of the high-field “Z” resonance over a wide range of frequencies 
(Figure S7) allowed determination of the D parameter in the S = 2 state of + 2.11 cm1 and gz = 
2.10. If the zfs tensors of two ions were collinear, the D found above would imply that D on 
single ions is +6.33 cm1, neglecting the D12 term in eq 1.
64 However, there are complicating 
factors. The two nickel ions in our system are non-equivalent, thus their g matrices and the zero-
field splitting tensors must be different. The molecular structure indicates that neither the g 
tensors of two ions nor their zfs tensors can be coaxial. In the EPR spectra of the dinuclear 
systems, the coupled g is observed and the zero-field splitting in the coupled states is affected by 
the zero-field splitting on the separate ions and by the anisotropic metal-metal interactions. The 
zero-field splitting of the coupled states depends not only on the {D1}, {D2} and {D12} component 
magnitudes but also on their orientation. This information is not available experimentally. 
Although DFT is not expected to provide correct magnitudes of the zfs parameters, calculations 
were performed in order to gain insight into the orientation of the {D1} and {D2} tensors and g 
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matrices of eq 1. The calculations, again performed by using ORCA, indicate that the “z” axis of 
the {D1} tensor forms an angle of 26 deg with the {D2} tensor “z” axis. With this arrangement it 
was found that D = +7.8 cm1 and E = +2.2 cm1 on each Ni ion are required to calculate the 
resonances marked with * and + in Figure 8 at right positions, assuming that the Ni ions are 
equivalent and neglecting the {D12} term in eq 1. It does not seem that we can extract more from 
our EPR data because of the lack of symmetry in the molecule. An additional aspect is that in the 
absence of the inversion center the antisymmetric exchange (Dzialoshiskii-Moriya interaction)82 
cannot be ruled out. High-field EPR studies on more symmetric systems were considerably more 
successful.70  
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Figure 7. EPR spectra of 1 recorded at 3 K with the microwave frequencies as indicated. The 
resonance marked with * was identified as the |2> ↔ |1> transition and was used to determine 
D = +2.11 cm1 and gz = 2.10 within the "giant spin" formalism. That resonance would be frozen 
out at 3 K if D were negative. The line marked with + also appears to be a |2> ↔ |1> 
transition. When the frequency is lowered below 222 GHz, that transition moves to a higher field 
showing that the MS levels involved are split in zero magnetic field by slightly more than 7.41 
cm1 (corresponding to the 222.4 GHz quantum energy). The E parameter of 0.52 cm1 could be 
estimated. 
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Figure 8. Energy levels calculated using the spin Hamiltonian (4) with D1 = D2 = 7.8 cm
1, E1= 
E2 = 2.2 cm
1, J = 11 cm1 and gz = 2.10. The magnetic field is along the Z axis of the coupled 
system, that is along the bisector of the Z1 and Z2 axes of the Ni(II) ions. Transitions expected at 
222.4 GHz are shown as vertical purple lines. * and + mark the same transitions as in Figure 7. 
Solution Chemistry 
Lipophilicity. The hydro-lipophilic character of dm-L-Pro-FTSC, its nickel(II) and copper(II) 
complexes 3 and 6, as well as of both zinc(II) complexes of L-Pro-FTSC and D-Pro-FTSC (7 and 
8) was studied at pH 7.4 via the partitioning between n-octanol and water. The data are 
summarized in Table S1. The enantiomers of the zinc(II) complexes of Pro-FTSC have similar 
logD7.4 values (L: −1.41(9); D: −1.56(5)) indicating rather hydrophilic character. However, they 
are slightly more lipophilic than the ligands alone (logD7.4 <  −1.7).
49  
The nickel(II) complexes with L-Pro-FTSC and D-Pro-FTSC (1 and 2) were found to be very 
hydrophilic and practically no metal complex could be detected in the organic phase after 
partitioning. Therefore, only a threshold limit could be estimated for their distribution 
coefficients (logD7.4 < −1.7) as in case of the ligands alone.
49 The dimethyl derivatives as 
expected were still hydrophilic, but appreciably more lipophilic than nonmethylated compounds. 
 
Proton Dissociation Processes of the Ligand L-Pro-FTSC. pKa values of L-Pro-FTSC (see 
Chart 1) were determined in aqueous solution by the combined approach of pH-potentiometric, 
UV–vis and 1H NMR titrations in our previous work49 and data obtained here were found to be 
identical with them. Although, this organic compound consists of four dissociable protons 
(COOH, NProH
+, NpyridineH
+ and NhydrazinicH) only three pKa values can be determined in the 
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studied pH-range. pK1 (1.86) most probably belongs to the deprotonation of the COOH moiety 
(partly overlapped with the deprotonation of NpyridineH
+) and pK2 (8.78) and pK3 (11.08) to 
NProH
+ and the hydrazinic-NH functional groups, respectively. It is noteworthy that the ligand is 
mainly present in its neutral form at pH 7.4 adopting a zwitterionic structure, which results in 
excellent water-solubility and a fairly hydrophilic character.49  
Complex Formation of L-Pro-FTSC with Zinc(II) and Nickel(II) in Aqueous Solution. 
Complex equilibria in water were investigated by pH-potentiometry in all cases and 
stoichiometries and cumulative stability constants of the metal complexes furnishing the best ﬁts 
to the experimental data are listed in Table 2. The recorded titration curves indicate that L-Pro-
FTSC is an efficient metal-ion chelator in a wide pH range for nickel(II) and zinc(II) ions.  
Representative titration curves (Figure 9) reveal that complex formation processes start at lowest 
pH in the case of nickel(II), while curves registered in the presence of zinc(II) are superimposed 
with that of the free ligand up to pH ~3.5. Fairly simple equilibrium model was obtained for all 
systems as formation of mono-ligand complexes ([MLH]+, [ML] and [MLH−1]
−) is the most 
probable (Table 2). In the protonated complexes [MLH]+, the proton can presumably be 
attributed to the non-coordinating hydrazinic N2 atom, while [ML] contains the completely 
deprotonated ligand. pK values of complexes [MLH]+ are significantly lower than pK2 (NProH
+) 
and pK3 (hydrazinic-NH) of the ligand in all cases, which strongly suggests the involvement of 
the Pro nitrogen into the coordination beside the thiosemicarbazide moiety in the complexes 
[ML]. Species [MLH−1]
− are regarded as mixed hydroxido complexes, i.e. [ML(OH)]−.       
 
Table 2. Cumulative (log (MpLqHr)) and Derived Stability Constants of the Nickel(II)−, 
Copper(II)− and Zinc(II)− L-Pro-FTSC complexesa [T = 298 K and I = 0.10 M (KCl)] 
 log 
[MLH]+ 
Log [ML] log [MLH−1]
− pK [MLH]
+ pMb 
nickel(II) 20.73(2) 15.78(3) 5.04(4) 4.95e 11.7 
copper(II)c 24.03 21.64 9.59 2.39 17.5 
zinc(II) 18.28(3) 13.31(2) − 4.97d 9.2 
aThe numbers in parentheses are standard deviations of the quoted log values 
determined by pH-potentiometry. Proton dissociation constants of the ligand: pK1 = 
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1.86, pK2 = 8.78 and pK3 = 11.08 taken from reference 49. 
bpM = −log[M] at pH 
7.40; cL/cM = 10; cM = 0.001 mM. 
cData are taken from ref. 49. dpK = 4.98(1) 
calculated from the 1H NMR values of the CH=N protons of the bound ligand.  
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Figure 9. Representative pH-potentiometric titration curves for ligand L-Pro-FTSC (×), zinc(II)– ligand 
(○) and nickel(II)– ligand (●) systems  [cL = 0.0019 M; M:L = 1:1.1 (a) and 1:2.3 (b); T = 298 K and I = 
0.10 M (KCl) in water]. Negative base equivalent values mean an excess amount of acid. 
 
Direct comparison of the overall stability constants (log) represents well the stability rank order 
of the metal complexes formed with the studied ligand: nickel(II) > zinc(II). It is noteworthy that 
copper(II) forms complexes with L-Pro-FTSC with unquestionably higher stability compared 
with these bivalent metal ions. First of all pM values have been computed in order to compare 
the extent of complex formation at physiological pH (Table 2). The higher pM value represents 
stronger chelating ability. pM values calculated show that the ligand effectiveness is increased in 
the following order: zinc(II) < nickel(II) < copper(II). Additionally the distribution of the mono 
complexes of zinc(II) and nickel(II) was calculated based on the determined stability constants at 
physiological pH at various total concentrations and depicted in Figure 10. Complexes [ML] 
predominate at this pH in all cases and as it is expected the partial dissociation resulting in free 
ligand and metal ion is more pronounced with decreasing total concentrations. Nickel(II) is able 
to preserve the original entity more efficiently owing to the higher stability of its complex, 
however even in the case of zinc(II) the decomposition of [ZnL] is only 8% at 1 M 
concentration at pH 7.4.  
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Figure 10. Concentration distribution curves for the metal(II) − L-Pro-FTSC systems at various 
total concentrations of the [ML] complexes at pH 7.40 [T = 298 K and I = 0.10 M (KCl)].  
 
In order to confirm the speciation obtained by pH-potentiometry for the zinc(II) − L-Pro-FTSC 
system 1H NMR spectroscopic measurements were applied. Slow ligand-exchange processes are 
seen with respect to the NMR time scale as the chemical shifts of the protons of the free and Zn-
bound ligand are observed separately (Figures 11 and S8). 
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Figure 11. Low-field region of the 1H NMR spectra recorded for the zinc(II) − L-Pro-FTSC 
system at the indicated pH values. Black symbols are shown for the bound ligand and red 
symbols for the nonbound ligand: ●: CHAr(6); ○: CHAr(4); □: CHAr(5); ■: CH=N; [cL = 1.0 mM; 
Zn:L = 1:2; T = 298 K and I = 0.10 M (KCl); 10% D2O].   
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Peaks belonging only to the nonbound ligand are seen at pH < ~4 and a new set of signals 
appears additionally with increasing pH, which belongs, most probably, to the protonated 
complex [ZnLH]+. Its deprotonation is accompanied by significant electronic shielding effects, 
namely an upfield shift of the peaks in the low-field region of the spectra. pK value of [ZnLH]+ 
calculated on the basis of the change of the signals of the CH=N protons of the bound ligand 
(Table 3) is in good agreement with that obtained from the pH-metric titration data. The peaks of 
species [ZnL] have constant positions at pH 7 − 11.5, which strongly suggests that the formation 
of a mixed-hydroxido complex [ZnL(OH)]− is not probable in this pH range. The integrated 
areas of the corresponding CH=N peaks of the bound and nonbound ligand could be calculated 
and converted to molar fractions, which were also computed under the same conditions based on 
the stability constants obtained by pH-potentiometry (Figure 12). The strong correlation between 
the data of the two independent methods supports the accuracy of the stability constants 
determined. 
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Figure 12. Concentration distribution curves of the zinc(II) − L-Pro-FTSC system at 1:1 (a) and 
1:2 (b) metal-to-ligand ratios obtained with the help of the stability constants (solid lines) 
together with the summed molar fraction of the bound ligand calculated (dashed line) and 
estimated from the integrated area of the signals of the CH=N proton (×) [cL = 1.0 mM; T = 298 
K and I = 0.10 M (KCl)].  
 
In the case of the outstanding high stability [CuL] complex of L-Pro-FTSC the coordination of 
the COO− and proline-N functionalities of the Pro moiety in addition to the (Npyr,N,S
−) donor set 
of thiosemicarbazide moiety could be proved both in solution and in solid phase in our previous 
work.49 The relatively high stability of the [ZnL] complex, which predominates at neutral pH 
even at micromolar concentrations, supports a similar binding pattern in solution. Moreover, the 
pentadentate (Npyr,N,S
−,COO−,NPro) coordination mode of L-Pro-FTSC to zinc(II) was also 
confirmed by single-crystal X-ray diffraction (Figure 4). 
 
The pentadentate binding of the ligand was also found in the case of nickel(II) in the solid phase, 
although the thiosemicarbazone sulfur atom acts as a bridging ligand in the dinuclear species 
crystallized out from the solution (Figures S1 and 1, 2). The pH-potentiometric titration curves 
for the nickel(II) − L-Pro-FTSC system could be fitted by the assumption of monomer complexes 
(Table 2), however this method has limitations in distinguishing between the formation of 
mononuclear and dinuclear species with the same metal-to-ligand ratio; therefore clarifying the 
actual coordination mode of the nickel(II) complexes in solution is more difficult. In order to 
confirm the speciation model obtained by pH-potentiometry and to get an insight into the 
geometry of the complexes UV–vis spectrophotometric and 1H NMR measurements were 
performed. According to the electronic absorption spectra (Figure 13), formation of octahedral 
nickel(II) complexes is probable with this ligand in the measured pH range due to the lack of the 
characteristic bands of the square-planar complexes in the visible region. Additionally, the pH-
dependent 1H NMR spectra (Figure 14a) represent broad signals accompanying the formation of 
the nickel(II) complexes (Figure 14b), which strongly suggests the presence of high-spin, 
paramagnetic species with octahedral geometry in solution. 
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Figure 13. UVvis spectra recorded for the nickel(II) − L-Pro-FTSC system at various pH 
values; [cL = 0.160 mM; Ni:L = 1:1; l = 0.5 cm; T = 298 K and I = 0.10 M (KCl)]. Inset shows 
the pH-dependence of the absorbance values at 374 nm for the same system (○) together with 
those recorded for the ligand alone (♦) and at 1:2 metal-to-ligand ratio (×) for comparison.  
 
On the other hand, UV–vis spectra at 1:1 metal-to-ligand ratio were measured in a wide 
concentration range (1 M – 0.8 mM) at pH 7.4. A clear linear correlation was found between 
the absorbance and concentration (Figure S9) representing the unchanged molar absorptivity (), 
thus unchanged species (ratio) in the studied concentration range. Dilution generally can shift the 
monomer/dimer equilibrium to the direction of dissociation affecting the  values as the ratio of 
the mononuclear and dinuclear species would change. Thus, the formation of only monomer 
[NiL] species in solution is more probable due to the constant  values.   
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Figure 14. Low-field region of the 1H NMR spectra recorded for the nickel(II) − L-Pro-FTSC 
system at the indicated pH values (a) [cL = 1.0 mM; Ni:L = 1:1; T = 298 K and I = 0.10 M (KCl); 
10% D2O] and concentration distribution curves for the same system (b). 
 
Stability of the Zinc(II) Complex of L-Pro-FTSC in Minimum Essential Medium (MEM) 
and its Interaction with HSA. MEM is usually used for the in vitro cytotoxicity studies and 
contains various amino acids which can potentially compete for the metal ion with the original 
ligand. To assess the stability of the [ZnL] complex of L-Pro-FTSC in the MEM, 1H NMR 
spectra of the complex were measured in this medium and in aqueous solution at pH 7.40 for 
comparison (Figure S10). The peaks of [ZnL] in MEM seem to remain unchanged compared to 
those detected in water and no free ligand is liberated due to a possible ligand displacement by 
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the amino acids. This provides strong evidence that the complex is stable in MEM. (Since 
nickel(II)  complexes possess log values by two orders of magnitude higher than those of 
zinc(II), no ligand displacement reactions are expected in MEM.) 
  
Competition reaction for the zinc(II) ion between L-Pro-FTSC and the most abundant blood 
serum protein, HSA was followed by 1H NMR spectroscopy. HSA serves as a transport vehicle 
for a wide variety of endogenous species such as copper(II) and zinc(II) ions and exogenous 
compounds and various pharmaceuticals. At the proposed Zn-binding site of HSA (Multi-Metal 
Binding Site) two His N atoms, an Asn carboxylate, an Asp carboxylate, and a water molecule 
are coordinated to the metal ion.83 The conditional binding constants of HSA for zinc(II) under 
physiological conditions are given in the literature as logK’ ~7.1–7.9.84 The 1H NMR spectrum 
recorded in the presence of HSA (Figure 15) clearly shows the partial displacement of L-Pro-
FTSC by the protein (~30%) under the given condition. Beside HSA, human serum transferrin 
(Tf) has also zinc(II) binding ability at the iron-binding sites;85 however, the concentration of Tf 
is approximately 17 times lower compared to that of HSA. Concentration distribution curves 
were computed for the zinc(II) complex of L-Pro-FTSC in the presence of these serum proteins 
at pH 7.4 at various total concentrations taking into consideration the stability constants of the 
zinc(II) complexes of the ligand, HSA and Tf (Figure S11a). These calculations reveal that ~30% 
of zinc(II) is bound to HSA at mM concentrations (as the 1H NMR spectrum also showed in 
Figure 15), while more than 80% at 10 M. The role of Tf seems to be almost negligible in this 
concentration range. Based on similar computational modelings, it can be concluded that the 
higher stability nickel(II) and copper(II) complexes are able to preserve their original 
composition stronger in the presence of the serum proteins (Figure S11b,c).86 
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Figure 15. Low-field region of the 1H NMR spectra of HSA, complex [ZnL] of L-Pro-FTSC 
with HSA and in HEPES buffer (20 mM) at pH 7.40 and for L-Pro-FTSC with HSA [cL = 1.0 
mM; cHSA = 0.63 mM; T = 298 K and I = 0.10 M (KCl); 10% D2O]. Peaks framed up correspond 
exclusively to the nonbound ligand. 
 
Cytotoxicity in Cancer Cell Lines. The antiproliferative activity of the investigated compounds 
(13 and 68) was evaluated for 48 h of continuous drug action, using colorimetric MTT assay. 
The study was performed in several human neoplastic cell lines (HeLa, FemX, A549, MDA-MB-
453), and one human fetal lung fibroblast cell line (MRC-5), which was used as a noncancerous 
model for the in vitro toxicity evaluation. The obtained cytotoxicity results for the nonmethylated 
metal-free hybrids L-Pro-FTSC and D-Pro-FTSC and their nickel(II), copper(II) and zinc(II) 
complexes revealed that all compounds possessed poor activity (IC50 > 300 μM) against all cell 
lines used (HeLa, FemX, MDA-MB-453). Complex formation of the FTSC-proline hybrids with 
nickel(II), copper(II) and zinc(II) (1, 2, 4, 7 and 8)  does not enhance antiproliferative effects in 
vitro. 
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We further investigated the antiproliferative activity of the dm-L-Pro-FTSC hybrid and its 
copper(II) and nickel(II) complexes. The results shown in Table 3 indicate that dimethylation 
improves the cytotoxicity of the hybrid (IC50(dm-L-Pro-FTSC) < IC50(D-Pro-FTSC and L-Pro-
FTSC). Complex formation of dm-L-Pro-FTSC with copper(II) (complex [Cu(dm-L-Pro-FTSC)] 
(6)) significantly increases cytotoxicity towards HeLa and MRC5 cell lines compared to dm-L-
Pro-FTSC hybrid alone (IC50 values 98.3 ± 5.5 and 69.4 ± 4.7 µM, compared to 224.6 ± 6.4 and 
178.4 ± 1.5 µM, respectively). These results, showing that dimethylation has a favourable impact 
on cytotoxicity, are in accordance with the previously reported studies.54,87 
Table 3. Results of MTT assay presented as IC50 (µM) values after 48 h incubation time. IC50 
values were calculated as mean values obtained from two to three independent experiments and 
quoted with their standard deviations. 
IC50/µM - (mean ± SD) 
Compound/cell line HeLa A549 MRC5 
L-Pro-FTSC > 300 > 300 > 300 
dm-L-Pro-FTSC 224.6 ± 6.4 204.3 ± 4.8 178.4 ± 1.5 
[Ni(dm-L-Pro-FTSC2H)]2 (3) > 300 > 300 > 300 
[Cu(dm-L-Pro-FTSC2H)] (6) 98.3 ± 5.5 176.8 ± 1.7 69.4 ± 4.7 
CDDPa 7.8 ± 2.3 17.2 ± 0.7 30.3 ± 3.0 
       The sign > (in front of the maximum value of the concentration) indicates that IC50 value is not 
       reached in the examined range of concentrations. Compounds contain co-crystallized solvent        
       (see Experimental section).   
       a taken from ref. 88 
Ribonucleotide reductase inhibition capacity. The reduction of the tyrosyl radical content in 
human R2 RNR protein by L-Pro-FTSC and dm-L-Pro-FTSC hybrids, and complexes 4, 6, and 7 
was monitored by EPR spectroscopy. The hR2 protein exhibits an EPR spectrum that arises from 
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the tyrosyl radical associated with enzyme activity (Figure 16b inset).89 It was observed that in 
the non-reducing conditions, the compounds are not active in tyrosyl radical destruction (Figure 
16a).  Moreover, complex 4 caused a small increase in tyrosyl radical content, an effect which 
was previously observed when mouse R2 protein (mR2) was incubated with only DTT.24,90 An 
increase in radical content is caused by the continued radical reconstitution process which 
requires the presence of oxygen. This result indicates that in the absence of a reductant, complex 
4 may have a protective role for the tyrosyl radical in hR2.  
 
Figure 16. Tyrosyl radical reduction in human R2 RNR protein in (a) absence, and (b) presence 
of the external reductant DTT, by ligands L-ProFTSC (black trace), and dm-L-Pro-FTSC (blue 
trace), and complexes 4 (red trace), 6 (magenta trace), and 7 (green trace). The samples contained 
20 μM hR2 protein in Tris buffer, pH 7.60 / 100 mM KCl / 5% glycerol, 20 μM compound (1% 
(w/w) DMSO/H2O) and 2 mM DTT (only b). Error bars are standard deviation from two 
independent experiments. Inset shows EPR spectrum of the tyrosyl radical in hR2 RNR protein at 
20 K. Experimental conditions are given in the Experimental section.  
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In the presence of an external reductant (DTT), all compounds showed appreciable radical 
destruction capacity compared to the nonreducing conditions (Figure 16b). The reduction by 
complex 4 was more efficient than by the ligand L-Pro-FTSC alone, indicating that the presence 
of the redox active copper(II) ion influences the inhibitory potential. Inhibition by complex 7 did 
not change markedly upon addition of DTT, as this compound contains zinc(II) which is redox 
inactive. Among the five tested compounds, dm-L-Pro-FTSC and complex 6 proved to be the 
best inhibitors, 6 being slightly more potent due to the presence of the copper(II) ion. The 
difference in the extent of the radical reduction observed between ligands L-Pro-FTSC and dm-L-
Pro-FTSC (and their corresponding copper(II) complexes, 4 and 6) indicates that the presence of 
two methyl groups increases the potency of the ligand. 
 
It is interesting to compare these compounds with Triapine which is an analog of 2-formylpyrine 
thiosemicarbazone. Triapine was shown to be a good mR224 and hR225 inhibitor. In both 
proteins, Triapine exhibited 70% radical reduction after 20 min in the absence of the reductant, 
and reduced the radical completely after 5 min in the presence of DTT. This suggests that the 
proline moiety decreases the inhibitory potential of the ligand. 
 
Conclusion 
Nickel(II) and zinc(II) complexes with chiral proline-thiosemicarbazone hybrids L- and D-Pro-
FTSC have been synthesized and characterized by standard analytical methods and in the case of 
complexes 13 also by single crystal X-ray diffraction. The temperature dependence of magnetic 
susceptibility, high-field EPR spectra and DFT calculations indicate ferromagnetic interaction 
between paramagnetic Ni(II) ions in 1 with the total spin ground state ST = 2. As these 
complexes possess excellent water solubility, the solution speciation of nickel(II) and zinc(II) 
complexes of L-Pro-FTSC has been characterized in pure aqueous solution via a combined 
approach using pH-potentiometry, 1H NMR spectroscopy and UV–vis spectrophotometry. 
Stability of the species formed is compared to that of copper(II) complexes. Exclusive formation 
41 
 
of the mono-ligand complexes such as [MLH]+, [ML] and [ML(OH)]– was detected. L-Pro-FTSC 
was found to act as a pentadentate ligand in solution coordinating the metal ions via the 
(Npyr,N,S
−,COO−,NPro) donor atoms. This binding mode was confirmed by X-ray crystallography 
in the case of the [ZnL] complex. On the other hand, nickel(II) forms a dinuclear complex with a 
central Ni(µ-S)2Ni core in solid state and the two metal ions are chelated by the 
(Npyr,N,S
−,COO−,NPro) donor set; however, the presence of monomeric species in solution is 
somewhat more probable. In the protonated [MLH]+ complexes the pentadenate 
(Npyr,N,S,COO
−,NPro) binding mode with a protonated noncoordinating hydrazine N
2 atom is 
suggested. Based on the determined stability constants the effectiveness of L-Pro-FTSC to 
chelate the metal ions is in the rank order zinc(II) < nickel(II) < copper(II). The predominant 
species at pH = 7.4 are [ML] complexes in all cases. Complexes of zinc(II), nickel(II) and 
copper(II) possess so high stability that they remain intact during dilution at physiological pH in 
the biologically relevant micromolar concentration range. Additionally, [ZnL] remains unaltered 
in MEM, while partial displacement of L-Pro-FTSC by HSA in the serum is probable, especially 
at lower concentrations of the complex. The compound L-Pro-FTSC was N-terminally 
dimethylated and the structures of its nickel(II) and copper(II) complexes were determined by X-
ray crystallography. Compounds prepared in this work were tested for antiproliferative activity 
in different human cancer cell lines. It was shown that dimethylation of terminal aminogroup in 
L- and D-Pro-FTSC resulted in antiproliferative activity of the hybrids. Coordination to 
copper(II) further enhances the cytotoxicity of the dimethylated hybrid. hR2 RNR inhibition 
capacity of selected compounds was also assayed. It was found that they are not active in tyrosyl 
radical destruction under nonreducing conditions, while they exhibit much stronger radical 
quenching capacity in the presence of the applied reductant DTT. The N-terminal dimethylation 
resulted in higher inhibitory potential of the ligand and its copper(II) complex. Further increase 
of the lipophilicity of proline-thiosemicarbazone hybrids via esterification of the proline moiety, 
and attachment of naphthyl, trimethylsilyl groups at the terminal nitrogen atom, which are 
underway in our laboratory, should result in more effective antiproliferative agents suitable for 
further development as potential anticancer drugs. 
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